CureMetrix Now Available on EnvoyAI Exchange

New Investigational Computer-Aided Detection Software for Improved Mammography Readings Now Available on the First AI Marketplace
SAN DIEGO - May 15, 2018 - PRLog -- CureMetrix (® and EnvoyAI (® today announced a new collaboration to provide hospitals and clinics with access to investigational, artificial intelligence-based computer aided detection (AI-CAD) software for 2D digital mammography via the EnvoyAI Exchange platform.

CureMetrix cmAssist® and cmTriage ® are investigational software designed to improve outcomes by combining the artificial intelligence of the algorithm with the "real" intelligence of a radiologist. "Medical imaging is at the forefront of the adoption curve for artificial intelligence in healthcare.  Radiologists recognize the opportunity to deploy AI to help optimize clinical workflow, improve clinical efficacy, help doctors become more efficient and improve outcomes for their patients," CureMetrix CEO, Kevin Harris, says.  "Radiologists can now access our software through EnvoyAI to conduct studies and help us validate that we are developing a tool that is truly valuable and useful in the clinic."

Through the collaboration with EnvoyAI and their parent company TeraRecon, hospitals will be able to access the power of CureMetrix AI-CAD with the push of a button.  The cloud-based, HIPAA-compliant, and vendor agnostic solutions allows for fast and easy deployment with little impact on IT resources.

"CAD solutions on the market today haven't lived up to their promise. A key challenge has been the high number of false positives, which leads to an increase in recall rates. We are excited about this partnership with CureMetrix because they are developing a CAD that works - a tool that addresses both sensitivity and specificity that radiologists can confidently rely on," says Dr. Steven Rothenberg, Chief Medical Officer of EnvoyAI. "Our number one goal is to empower physicians by giving them access to the best algorithms available."

Over 500,000 images from leading institutions across the US are being used to train and validate the CureMetrix algorithm so it can recognize and quantify regions of interest on a mammogram. Independent testing by leading institutions has shown that the CureMetrix algorithm has best-in-class efficacy and is becoming the leader in AI-CAD for the breast.  The company is currently working towards FDA approval for its products.

For more information or to participate in a study to evaluate the potential power of the integrated solution contact CureMetrix at or EnvoyAI at

About CureMetrix

CureMetrix® was founded in 2014 on the belief that better medical image analysis technology could lead to better outcomes for breast cancer patients. The company is developing investigational, physics-based artificial intelligence and deep learning solutions to help radiologists achieve more accurate readings of breast images. Through its research partnerships with leading hospital radiology departments, CureMetrix has evaluated more than 500,000 mammogram images to identify potential false negatives, which are undiagnosed cancers, and false positives, which are unnecessary recalls of patients to review anomalies that turn out to be normal. False negatives can occur at a rate of about one in five breast cancers.1 False positives affect 7-12 percent of all women after an initial mammogram.2 Reducing false positives could save a significant portion of the $4 billion per year spent on unneeded and sometimes invasive procedures such as biopsies.3 More importantly, reducing false negatives could save lives as well as reduce the cost and difficulty of cancer treatment through early detection.

Our goal is to create CAD that Works®. Improving computer-aided detection through a robust physics-based algorithm for detecting cancer empowers radiologists, supports their patients and reduces costs while improving clinical outcomes. To learn more about CureMetrix, visit




About EnvoyAI

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

Media Contact
Elise Crispen, Director of Marketing, CureMetrix
Source: » Follow
Email:*** Email Verified
Tags:Artificial Intelligence, Breast Cancer, Medical Imaging
Location:San Diego - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share